

## List of Figures

Figure No.	Figure Captions	Page No.
2.1	Pathological mechanisms responsible for diabetic cardiomyopathy	23
2.2	Defective signalling pathways in diabetic cardiomyopathy	25
2.3	Role of AMPK in the regulation of cell death	28
2.4	Role of Nrf2 signalling in oxidative stress	33
2.5	Role of HO-1 in diabetic cardiomyopathy	36
4.1	Study design for objective-I	61
4.2	Study design for objective-II	62
4.3	Study design for objective-III	62
4.4	Myocardial ischemia-reperfusion by LAD artery ligation	67
5.1	Effect of PT administration on OGTT of experimental rats. A) Blood glucose vs time plot graph of OGTT B) Area under the curve of blood glucose (AUC) levels of OGTT	95
5.2	Effect of PT on blood pressure of experimental rats. A) Systolic blood pressure B) Diastolic blood pressure C) Mean arterial pressure	97
5.3	Effect of PT on lipid profile, cardiovascular risk indices and antiatherogenic index (AAI) of experimental rats. A) Total cholesterol B) Triglycerides C) HDL-C D)LDL-C E) VLDL-C F) Total cholesterol/HDL-C ratio G) LDL-C/HDL-C ratio H) AAI	99
5.4	Effect of PT treatment on A) serum glycated haemoglobin (HbA1c) levels B) serum uric acid levels C) serum peroxynitrite levels D) serum hydrogen sulphide levels after 8 weeks of fructose feeding	101
5.5	Effect of PT on the cardiac oxidative stress in control and fructose-fed diabetic rats. A) Cardiac TBARS levels B) cardiac ROS levels C) cardiac hydrogen peroxide levels D) cardiac peroxynitrite levels	106
5.6	Effect of PT on the cardiac antioxidant defence system in control and fructose-fed diabetic rats. A) myocardial SOD levels B) myocardial catalase levels C) myocardial GSH levels and D) myocardial GPx levels	107
5.7	Effect of PT supplementation on cardiac and plasma inflammatory cytokines of control and fructose-fed diabetic rats. A) cardiac IL-1 $\beta$ levels B) cardiac IL-6 levels C) cardiac TNF- $\alpha$ levels D) plasma IL-1 $\beta$ levels E) plasma IL-6 levels F) plasma TNF- $\alpha$ levels	109

5.8	Effect of PT treatment on inflammatory response in cardiac tissues of control and fructose-fed diabetic rats. A) NF- $\kappa$ B mRNA expression B) NF- $\kappa$ B protein expression C) TLR4 mRNA expression D) NLRP3 mRNA expression E) ASC mRNA expression	111
5.9	Effects of PT administration on the expression of the mitochondrial biogenesis proteins, Nrf2, HO-1 in the hearts of control and fructose-fed diabetic rats. Cardiac A) mRNA expression of PGC-1 $\alpha$ B) protein expression of PGC-1 $\alpha$ C) protein expression of Complex III D) protein expression of Complex V E) mRNA expression of Nrf2 F) mRNA expression of HO-1	113
5.10	Effects of PT administration on the protein expression levels of AMPK/Nrf2/HO-1 signalling components in the hearts of control and fructose-fed diabetic rats. Myocardial expression of A) AMPK, p-AMPK B) Nrf2 C) HO-1	116
5.11	Effect of PT on myocardial IR injury in diabetic rats (infarct size, necrosis, and oxidative stress). (A) Cardiomyocytes cross-sectional area 8 weeks post-treatment by H-E staining. (B) Myocardial infarct size in diabetic rats subjected to 30 minutes ischemia, followed by 2 hours reperfusion. (C) The area at risk is expressed as percentage of left ventricle (D) Plasma lactate dehydrogenase (LDH) levels. (E) Plasma creatine kinase-MB (CK-MB) levels. (F) Plasma free 8-isoprostane levels	120
5.12	Effect of PT on cardiac apoptosis in diabetic rats. (A) Terminal deoxynucleotidyl nick-end labelling (TUNEL) staining in myocardial IR heart tissue from the experimental groups. (B) Bcl-2/Bax ratio (C) cleaved caspase-3/caspase-3 ratio	122
5.13	Effect of PT treatment on AMPK phosphorylation in heart tissues of diabetic rats	123
5.14	Dose selection of PT for in-vitro cell line studies based on MTT and LDH assays. (A) Cell viability in primary cells administered PT (0.1, 0.5, 1 $\mu$ M) during HR. (B) LDH assay in primary cells administered PT (0.1, 0.5, 1 $\mu$ M) during HR	124
5.15	Effect of PT on HR-induced injury in primary rat cardiomyocytes (cell viability, LDH release and oxidative stress) under normal and diabetic conditions. (A) Cell viability in different treatment groups. (B) LDH release in different treatment groups. (C) Oxidative stress determined by DHE staining	126
5.16	Effect of PT on AMPK phosphorylation in rat primary cardiomyocytes	128

5.17A	Effect of PT on cardiac apoptosis in primary cardiomyocytes under normal and diabetic conditions. (A) HR-induced apoptosis as determined by TUNEL staining.	131
5.17B	Effect of PT on cardiac apoptosis in primary cardiomyocytes under normal and diabetic conditions. (B) Bcl-2/Bax ratio.	132
5.17C	Effect of PT on cardiac apoptosis in primary cardiomyocytes under normal and diabetic conditions. (C) Cleaved caspase-3/caspase-3 ratio	133